# Supernus Pharmaceuticals, Inc. (SUPN)

> Source: Nexqual · https://nexqual.com/SUPN · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Supernus Pharmaceuticals, Inc. (SUPN), nexqual.com/SUPN" · informational, not investment advice.

**Price:** USD 39.57 (-1.52% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 40.18 · day 39.36–41.31 · 52w 39.36–59.68 · market cap $2.30B · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $830M, net income -$110M (-13.2% margin), free cash flow $18.8M (SEC filings).
- 1 of 80 tracked superinvestors hold SUPN (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.25 on a 1–5 scale) (4 analysts), mean target USD 60.5 (range 55–67).
- Total return with dividends: 1Y -20.5% vs S&P 500 +18.1%; 5Y +25.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD 0.56, revenue estimate $221M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $580M | $667M | $608M | $662M | $719M | $830M |
| Gross profit | — | $580M | $524M | $584M | $644M | — |
| Operating income | $86.0M | $46.1M | -$5.3M | $81.7M | -$62.3M | -$130M |
| Net income | $53.4M | $60.7M | $1.3M | $73.9M | -$38.5M | -$110M |
| EPS (diluted) | $0.98 | $1.04 | $0.02 | $1.32 | -$0.68 | — |
| Free cash flow | — | $116M | $111M | $171M | $46.0M | $18.8M |
| Gross margin | — | 86.9% | 86.2% | 88.2% | 89.6% | — |
| Operating margin | 14.8% | 6.9% | -0.9% | 12.3% | -8.7% | -15.7% |
| Net margin | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% | -13.2% |
| Revenue growth | +11.4% | +15.1% | -8.9% | +8.9% | +8.6% | — |
| Cash + short-term investments | $340M | $461M | — | — | $128M | — |
| Total debt | $379M | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 2.8x · P/FCF 122.6x · P/B 2.2x · FCF yield 0.82% · Earnings yield -4.77%
P/E at fiscal year-ends: Dec 2024 27.4x, Dec 2023 1220.6x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold SUPN. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Third Avenue Management |  | 1.14% | $7.1M | Unchanged |

## Analysts
Consensus Buy (mean 2.25 on a 1–5 scale), 4 analysts; mean target USD 60.5 (low 55, high 67).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-09 | Cantor Fitzgerald | Target raised | Overweight | $63 → $67 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -20.5% | +25.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -20.5% | +4.5% |
| Volatility (annualized) | 37.1% | 31.5% |
| Max drawdown | -30.6% (Nov 2025→Oct 2026) | -43.4% (Jan 2023→Oct 2023) |

## Peers (Drug Manufacturers - Specialty & Generic)
HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · KNSA (Kiniksa Pharmaceuticals Interna) USD 79.94 +1.80%

## More
Full page: https://nexqual.com/SUPN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt